1. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89 Zr- and 64 Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.
- Author
-
Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, Remaud-Le Saëc P, Bourgeois M, Chouin N, Rbah-Vidal L, Tripier R, Haddad F, Kraeber-Bodéré F, Bodet-Milin C, and Chérel M
- Subjects
- Animals, Antibodies, Monoclonal chemistry, Antibodies, Monoclonal immunology, Bone Neoplasms secondary, Cell Line, Cell Line, Tumor, Copper Radioisotopes adverse effects, Copper Radioisotopes chemistry, Female, Fluorodeoxyglucose F18 pharmacokinetics, Mice, Mice, Inbred C57BL, Multiple Myeloma pathology, Radioisotopes adverse effects, Radioisotopes chemistry, Radiopharmaceuticals adverse effects, Radiopharmaceuticals chemistry, Syndecan-1 chemistry, Tissue Distribution, Zirconium adverse effects, Zirconium chemistry, Bone Neoplasms diagnostic imaging, Copper Radioisotopes pharmacokinetics, Multiple Myeloma diagnostic imaging, Positron-Emission Tomography methods, Radioisotopes pharmacokinetics, Radiopharmaceuticals pharmacokinetics, Syndecan-1 immunology, Zirconium pharmacokinetics
- Abstract
Although positron emission tomography (PET) imaging with 18-Fluorodeoxyglucose (
18 F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a standard marker for the identification of myeloma cells and could be used in phenotype tumor imaging. In this study, we used an anti-CD138 murine antibody (9E7.4) radiolabeled with copper-64 (64 Cu) or zirconium-89 (89 Zr) and compared them in a syngeneic mouse model to select the optimal tracers for MM PET imaging. Then, 9E7.4 was conjugated to TE2A-benzyl isothiocyanate (TE2A) and desferrioxamine (DFO) chelators for64 Cu and89 Zr labeling, respectively.64 Cu-TE2A-9E7.4 and89 Zr-DFO-9E7.4 antibodies were evaluated by PET imaging and biodistribution studies in C57BL/KaLwRij mice bearing either 5T33-MM subcutaneous tumors or bone lesions and were compared to18 F-FDG-PET imaging. In biodistribution and PET studies,64 Cu-TE2A-9E7.4 and89 Zr-DFO-9E7.4 displayed comparable good tumor uptake of subcutaneous tumors. On the bone lesions, PET imaging with64 Cu-TE2A-9E7.4 and89 Zr-DFO-9E7.4 showed higher uptake than with18 F-FDG-PET. Comparison of both 9E7.4 conjugates revealed higher nonspecific bone uptakes of89 Zr-DFO-9E7.4 than64 Cu-TE2A-9E7.4. Because of free89 Zr's tropism for bone when using89 Zr-anti-CD138,64 Cu-anti-CD138 antibody had the most optimal tumor-to-nontarget tissue ratios for translation into humans as a specific new imaging radiopharmaceutical agent in MM.- Published
- 2019
- Full Text
- View/download PDF